Healthcare & Life Sciences Private Equity Deal Tracker: Sheridan Sells Dermatologists of Central States to SkyKnight

McGuireWoods LLP
Contact

Sheridan Capital Partners has announced the sale of Dermatologists of Central States (DOCS) to SkyKnight Capital.

DOCS, headquartered in Cincinnati, is a provider of management services to dermatology practices in the Midwest and Southeast United States. The organization has a presence in seven states: Illinois, Indiana, Michigan, North Carolina, Ohio, Pennsylvania and West Virginia.

Sheridan, based in Chicago, is healthcare-focused firm that concentrates on the lower middle market. Founded in 2012, the firm prefers to take control positions in healthcare providers and outsourced services as well as consumer health and products companies.

SkyKnight Capital, with locations in San Francisco and New York, is a private equity firm focused on healthcare and a few other sectors. Founded in 2015, the firm prefers to make minority and “small majority” investments typically in partnership with families and employees.

McGuireWoods LLP served as legal advisor to Sheridan.

Terms of the sale were not disclosed.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McGuireWoods LLP | Attorney Advertising

Written by:

McGuireWoods LLP
Contact
more
less

McGuireWoods LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.